Recursion Pharmaceuticals (RXRX) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Recursion Pharmaceuticals (RXRX) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 18.47% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 92.37% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.60 Bn | 944.55 Mn | -6.02 Mn | 41.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.97% |
| Dec 31, 2025 | 39.56% |
| Sep 30, 2025 | -69.29% |
| Jun 30, 2025 | -76.23% |
| Mar 31, 2025 | -121.60% |
| Dec 31, 2024 | -92.38% |
| Sep 30, 2024 | -3.04% |
| Jun 30, 2024 | -27.13% |
| Mar 31, 2024 | -39.87% |
| Dec 31, 2023 | -44.09% |
| Sep 30, 2023 | -48.62% |
| Jun 30, 2023 | -15.89% |
| Mar 31, 2023 | -16.67% |
| Dec 31, 2022 | 0.67% |
| Sep 30, 2022 | -34.24% |
| Jun 30, 2022 | -52.44% |
| Mar 31, 2022 | -82.17% |
| Dec 31, 2021 | -152.36% |
| Sep 30, 2021 | -103.81% |
| Jun 30, 2021 | -132.96% |